Free Trial

Theratechnologies Q2 2023 Earnings Report

Theratechnologies logo
C$2.10 +0.04 (+1.94%)
As of 03:59 PM Eastern

Theratechnologies EPS Results

Actual EPS
-C$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Theratechnologies Revenue Results

Actual Revenue
$23.84 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Theratechnologies Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Theratechnologies Earnings Headlines

TSX Slumps Amid Tariff Suspense
Markets Flat as Investors Brace for Tariffs
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Theratechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theratechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theratechnologies and other key companies, straight to your email.

About Theratechnologies

Theratechnologies (TSE:TH) Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

View Theratechnologies Profile

More Earnings Resources from MarketBeat